menu
    • menu

    Company profile for Wugen

    NEW Drugs in Dev: 3
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Wugen is dedicated to developing off-the-shelf cell therapies for treatment of cancer These cell therapy drugs originate from healthy donors and are amplified in order to enhance cancer cell elimination. Our Immuno-Oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML), multiple myeloma (MM) and T-cell malignancies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    WugenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4340 Duncan Ave Suite 302 St. Louis, MO 63110
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://wugen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Wugen To Present Long-Term Follow-Up Data For CD7 CAR-T Therapy
    Wugen To Present Long-Term Follow-Up Data For CD7 CAR-T Therapy

    05 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/05/3200578/0/en/Wugen-to-Present-Correlative-Data-and-Long-Term-Follow-Up-Updates-for-Off-the-Shelf-Allogeneic-CD7-Targeted-CAR-T-Cell-therapy-at-the-2025-ASH-Annual-Meeting.html

    GLOBENEWSWIRE
    05 Dec 2025
    Share Share
    HCW Biologics Congratulates Wugen on Successful Equity Financing
    HCW Biologics Congratulates Wugen on Successful Equity Financing

    18 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/18/3152497/0/en/HCW-Biologics-a-Shareholder-of-Wugen-Congratulates-Wugen-on-Its-Recent-Successful-Equity-Financing.html

    GLOBENEWSWIRE
    18 Sep 2025
    Share Share
    Wugen Secures $115M for Advancing WU-CART-007 CAR-T Therapy
    Wugen Secures $115M for Advancing WU-CART-007 CAR-T Therapy

    27 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/27/3139864/0/en/Wugen-Secures-115-Million-to-Advance-Pivotal-Study-of-First-in-Class-Allogeneic-CAR-T-Therapy-WU-CART-007.html

    GLOBENEWSWIRE
    27 Aug 2025
    Share Share
    Wugen Doses First Patients in Trial of CD7-Targeted CAR-T Therapy
    Wugen Doses First Patients in Trial of CD7-Targeted CAR-T Therapy

    20 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3046089/0/en/Wugen-Announces-Dosing-of-First-Patients-in-Pivotal-Trial-of-Off-the-Shelf-Allogeneic-CD7-Targeted-CAR-T-Cell-Therapy-WU-CART-007.html

    GLOBENEWSWIRE
    20 Mar 2025
    Share Share
    Wugen Appoints Jim Faulkner as CTO
    Wugen Appoints Jim Faulkner as CTO

    26 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/26/3032766/0/en/Wugen-Announces-Appointment-of-Jim-Faulkner-Ph-D-as-Chief-Technology-Officer.html

    GLOBENEWSWIRE
    26 Feb 2025
    Share Share
    Wugen to Present Clinical Data at 2024 ASH Meeting
    Wugen to Present Clinical Data at 2024 ASH Meeting

    05 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/05/2992546/0/en/Wugen-to-Present-Clinical-Data-at-the-2024-ASH-Annual-Meeting-Ahead-of-Pivotal-Trial-Launch-of-Off-the-Shelf-Allogeneic-CD7-Targeted-CAR-T-Cell-Therapy-WU-CART-007.html

    GLOBENEWSWIRE
    05 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search